MedTrace Logo

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2010-03-09

No results posted yet for this study

Summary

Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo

Conditions

Interventions

DRUG

rasagiline mesylate

0.5 mg rasagiline mesylate oral once daily

DRUG

1.0 mg rasagiline mesylate

1.0 mg rasagiline mesylate oral once daily

OTHER

Placebo

oral placebo once daily

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Ira Shoulson, MD · The Parkinson Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2003-01-31
Completion
2003-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203034 on ClinicalTrials.gov